These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11008324)

  • 41. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
    Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
    J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma.
    Hohaus S; Di Febo A; Storti S; Teofili L; Voso MT; Leone G
    Haematologica; 2004 Jun; 89(6):751-2. PubMed ID: 15194545
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group.
    Eich HT; Haverkamp U; Engert A; Kocher M; Skripnitchenko R; Brillant C; Sehlen S; Dühmke E; Diehl V; Müller RP
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):860-5. PubMed ID: 15925455
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades.
    Koumarianou AA; Xiros N; Papageorgiou E; Pectasides D; Economopoulos T
    Anticancer Res; 2007; 27(2):1191-7. PubMed ID: 17465262
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphoma (EORTC 20884).
    Aleman BM; Girinsky T; van der Maazen RW; Strijk S; Meijnders P; Bortolus R; Olofsen-van Acht MJ; Lybeert ML; Lievens Y; Eghbali H; Noordijk EM; Tomsic R; Meerwaldt JH; Poortmans PM; Smit WG; Pinna A; Henry-Amar M; Raemaekers JM; ;
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1184-90. PubMed ID: 15936157
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Perspectives of the management of childhood lymphoma: experience at Tygerberg Hospital, Western Cape, South Africa.
    Wessels G; Bernard Hesseling P
    Transfus Apher Sci; 2005 Feb; 32(1):27-31. PubMed ID: 15737871
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Use of risk-adapted programs of treatment of Hodgkin's disease in children and adolescents].
    Kuleva SA
    Vopr Onkol; 2008; 54(6):768-70. PubMed ID: 19241857
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease.
    Villani F; Busia A; Villani M; Laffranchi A; Viviani S; Bonfante V
    Anticancer Res; 2009 Feb; 29(2):777-83. PubMed ID: 19331235
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
    Majhail NS; Weisdorf DJ; Defor TE; Miller JS; McGlave PB; Slungaard A; Arora M; Ramsay NK; Orchard PJ; MacMillan ML; Burns LJ
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1065-72. PubMed ID: 17084370
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radiotherapy alone for lymphocyte-predominant Hodgkin's disease.
    Schlembach PJ; Wilder RB; Jones D; Ha CS; Fayad LE; Younes A; Hagemeister F; Hess M; Cabanillas F; Cox JD
    Cancer J; 2002; 8(5):377-83. PubMed ID: 12416895
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group.
    Schellong G; Dörffel W; Claviez A; Körholz D; Mann G; Scheel-Walter HG; Bökkerink JP; Riepenhausen M; Lüders H; Pötter R; Rühl U;
    J Clin Oncol; 2005 Sep; 23(25):6181-9. PubMed ID: 16135485
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Radiotherapy for advanced Hodgkin's disease.
    Gupta T; Sanghavi V; Laskar S
    N Engl J Med; 2003 Sep; 349(12):1187-8; author reply 1187-8. PubMed ID: 13679537
    [No Abstract]   [Full Text] [Related]  

  • 54. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
    Hudson MM; Krasin M; Link MP; Donaldson SS; Billups C; Merchant TE; Kun L; Billet AL; Kaste S; Tarbell NJ; Howard S; Friedmann AM; Hurwitz CA; Young JA; Marcus KC; Rai S; Cowan T; Weinstein HJ
    J Clin Oncol; 2004 Nov; 22(22):4541-50. PubMed ID: 15542805
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkin's disease.
    Gobbi PG; Broglia C; Bertè R; Petrilli MP; Molica S; Angrilli F; Iannitto E; Ghirardelli ML; Di Renzo N; Cavanna L; Ascari E
    Haematologica; 2000 Jul; 85(7):722-8. PubMed ID: 10897124
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MOPP, ABVD, or both to treat Hodgkin's disease.
    Martino R; Nomdedeu J; Brunet S
    N Engl J Med; 1993 Apr; 328(14):1045; author reply 1045-6. PubMed ID: 7680766
    [No Abstract]   [Full Text] [Related]  

  • 57. [A trial of applying an oily suspension of bleomycin endolymphatically in patients with Hodgkin's disease of the extraperitoneal lymph nodes].
    Ziółko E
    Pol Merkur Lekarski; 1997 Jul; 3(13):8-9. PubMed ID: 9432303
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prospective study of combined modality treatment or radiotherapy alone in the management of early-stage adult Hodgkin's disease.
    Yildiz F; Zengin N; Engin H; Güllü I; Barista I; Caglar M; Ozyar E; Cengiz M; Gürkaynak M; Zorlu F; Caner B; Atahan IL; Tekuzman G
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):839-46. PubMed ID: 15465201
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial.
    Hancock BW; Gregory WM; Cullen MH; Hudson GV; Burton A; Selby P; Maclennan KA; Jack A; Bessell EM; Smith P; Linch DC; ;
    Br J Cancer; 2001 May; 84(10):1293-300. PubMed ID: 11355937
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Results of a prospective protocol for the treatment of adult Hodgkin's disease].
    Meddeb B; Ben Lakhal R; Bel Hadj Ali Z; Ben Abid H; Hafsia R; Hafsia A
    Tunis Med; 1999 Dec; 77(12):614-20. PubMed ID: 10730152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.